Spero Therapeutics (SPRO) Competitors $1.90 +0.02 (+1.06%) Closing price 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. CMPX, ETON, ALMS, PRTA, CRVS, ERAS, ITOS, SLDB, ATXS, and NBTXShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Compass Therapeutics (CMPX), Eton Pharmaceuticals (ETON), Alumis (ALMS), Prothena (PRTA), Corvus Pharmaceuticals (CRVS), Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors Compass Therapeutics Eton Pharmaceuticals Alumis Prothena Corvus Pharmaceuticals Erasca iTeos Therapeutics Solid Biosciences Astria Therapeutics Nanobiotix Spero Therapeutics (NASDAQ:SPRO) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Do analysts rate SPRO or CMPX? Spero Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 163.16%. Compass Therapeutics has a consensus price target of $13.88, suggesting a potential upside of 284.35%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has more volatility & risk, SPRO or CMPX? Spero Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Does the media favor SPRO or CMPX? In the previous week, Spero Therapeutics and Spero Therapeutics both had 3 articles in the media. Spero Therapeutics' average media sentiment score of 1.65 beat Compass Therapeutics' score of 0.99 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of SPRO or CMPX? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SPRO or CMPX more profitable? Compass Therapeutics has a net margin of 0.00% compared to Spero Therapeutics' net margin of -110.35%. Compass Therapeutics' return on equity of -53.11% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics-110.35% -120.27% -55.61% Compass Therapeutics N/A -53.11%-46.14% Which has preferable valuation and earnings, SPRO or CMPX? Compass Therapeutics has lower revenue, but higher earnings than Spero Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$34.09M3.14-$68.57M-$0.98-1.94Compass Therapeutics$850K587.28-$49.38M-$0.45-8.02 SummaryCompass Therapeutics beats Spero Therapeutics on 13 of the 16 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$106.92M$3.09B$5.70B$10.26BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.9421.3175.8826.53Price / Sales3.14382.24492.67165.78Price / CashN/A44.4425.8129.90Price / Book2.249.6012.836.32Net Income-$68.57M-$53.28M$3.28B$270.12M7 Day Performance-4.04%0.28%0.17%2.12%1 Month Performance-0.52%4.54%4.54%6.31%1 Year Performance38.69%9.27%68.32%25.51% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.3774 of 5 stars$1.90+1.1%$5.00+163.2%+37.2%$106.92M$34.09M-1.94150News CoveragePositive NewsShort Interest ↓CMPXCompass Therapeutics2.2514 of 5 stars$3.44flat$12.89+274.7%+123.6%$475.69M$850K-7.6420ETONEton Pharmaceuticals2.2952 of 5 stars$17.78+0.6%$29.67+66.9%+245.2%$473.87M$39.01M-111.1320News CoveragePositive NewsALMSAlumis3.2878 of 5 stars$4.32-4.2%$20.17+366.8%-62.2%$469.33MN/A0.00N/APRTAProthena3.4225 of 5 stars$8.49-0.7%$19.75+132.6%-63.1%$460.25M$10.34M-1.51130News CoverageAnalyst RevisionCRVSCorvus Pharmaceuticals2.4933 of 5 stars$5.90-4.2%$15.00+154.2%+15.3%$459.01MN/A-5.8430Positive NewsERASErasca2.3727 of 5 stars$1.55-3.7%$3.71+139.6%-46.1%$456.71MN/A-3.44120Analyst DowngradeITOSiTeos Therapeutics3.4409 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences3.1281 of 5 stars$5.13-6.7%$15.00+192.4%-30.8%$428.28M$8.09M-1.83100Positive NewsAnalyst DowngradeATXSAstria Therapeutics2.858 of 5 stars$7.43-1.2%$29.00+290.3%-33.8%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.6266 of 5 stars$8.71+0.1%$8.00-8.2%+88.3%$417.11M$39.18M0.00100Upcoming EarningsShort Interest ↑Gap Up Related Companies and Tools Related Companies Compass Therapeutics Alternatives Eton Pharmaceuticals Alternatives Alumis Alternatives Prothena Alternatives Corvus Pharmaceuticals Alternatives Erasca Alternatives iTeos Therapeutics Alternatives Solid Biosciences Alternatives Astria Therapeutics Alternatives Nanobiotix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRO Stock Alerts